Compare ARAY & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | SERA |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6M | 77.2M |
| IPO Year | 2006 | 2021 |
| Metric | ARAY | SERA |
|---|---|---|
| Price | $0.39 | $1.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 78.6K |
| Earning Date | 04-29-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | $4.58 | $715.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.33 | $1.37 |
| 52 Week High | $2.10 | $4.20 |
| Indicator | ARAY | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 27.88 |
| Support Level | $0.33 | $1.37 |
| Resistance Level | $0.63 | $2.00 |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 27.75 | 9.00 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.